BAFNAPHARM

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 11-Nov-2016, regarding "Bafna Pharmaceuticals Limited has informed the Exchange the Outcome of Board Meeting held on 11th November, 2016".On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);The response of the Company is awaited.

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2016.

Bafna Pharmaceuticals Limited has informed the Exchange the Outcome of Board Meeting held on 11th November, 2016

Bafna Pharmaceuticals Limited has informed the Exchange vide letter dated November 01, 2016 that "This is regard with the intimation made under Regulation 29 of SEBI (LODR) Regulations, 2015. We wish to inform you that, the meeting of the Board of Directors of the Company is scheduled to be held on November 11, 2016 to consider among others, the Unaudited Financial Results for the quarter ended September 30, 2016. In our erstwhile communication, we had inadvertently mentioned Thursday instead of Friday."

Bafna Pharmaceuticals Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on the September 28, 2016 along with Report of Scrutinizer.

Bafna Pharmaceuticals Limited has submitted to the Exchange a copy of the Summary of Proceedings of the Annual General Meeting of the Company held on September 28, 2016.

Bafna Pharmaceuticals Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from September 22, 2016 to September 27, 2016 (both days inclusive) for the purpose of Annual General Meeting of the Company to be held on September 28, 2016.

Bafna Pharmaceuticals Limited has submitted to the Exchange a Copy of limited review report of the unaudited financial results of the Company for the three months period ended June 30, 2016.

Bafna Pharmaceuticals Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended June 30, 2016.

Bafna Pharmaceuticals Limited has informed the Exchange regarding the Results of Postal Ballot( including e-voting).

Bafna Pharmaceuticals Limited has submitted to the Exchange the details of voting results of the Postal Ballot results along with Scrutinizer report.

Bafna Pharmaceuticals Limited has submitted to the Exchange a copy of the Postal Ballot Notice, Pursuant to Section 110 of the Companies Act, 2013 read with the Companies ( Management and Administration) Rules, 2014.

Bafna Pharmaceuticals Limited has informed the Exchange the Submission of Resolution passed at the Meeting of the board of directors and Calender of events approved by the Directors.

Bafna Pharmaceuticals Limited has informed the Exchange that the Audit Report issued on the Financial results for the year ended March 31, 2016 (Standalone and Consolidated) is unmodified.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Auditors Report on Quarterly Financial Results and Year to Date Results of the Company.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Auditors Report on Quarterly Financial Results and Year to Date Results of the Company.

Bafna Pharmaceuticals Limited has informed the Exchange that the meeting of the Board of Directors considered and approve the proposal for Allotment of Equity Shares of 10,00,000 to Promoters and 30,00,000 Equity Shares to External investors (Non-Promoter) under Preferential allotment basis through Postal Ballot Process.

Bafna Pharmaceuticals Limited has informed the Exchange that the trading window for dealing with securities of the Company will be closed for the employees & Directors w.e.f. June 10, 2016 to till date of the Board Meeting (both days inclusive).

Bafna Pharmaceuticals Limited has submitted to the Exchange the standalone & consolidated financial results along with the Auditors Report for the period ended March 31, 2016.

Bafna Pharmaceuticals Limited has informed the Exchange that the Company confirms that as per the Company's internal code for Prevention of Insider Trading, the trading window for dealing in the securities of the Company by the Directors and employees will remain closed from the date of receipt of the communication till 48 hours after the announcement of financial results made the public, i.e. June 1, 2016.

Bafna Pharmaceuticals Limited has submitted to the Exchange vide letter dated April 7, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Bafna Pharmaceuticals Limited has informed the Exchange that the company has been registered with Department of Scientific & Industrial Research for the purpose of availing customs /central excise duty exemption in terms of Government notification No 24/2007 dated March 01, 2007 and central excise duty exemption in terms of notification No 16/2007 dated March 01, 2007and the registration is subject to conditions imposed by the DSIR. Further the Company inform that the company has got the renewal of recognition of In-house R&D units by the Department of Scientific and Industrial Research subjec

Bafna Pharmaceuticals Limited has informed the Exchange that Mr.M.R.Ramachandran, Chief Finanial Officer has submitted his resignation and reliveded from services of the company effective from the closing hours of March 03, 2016.

Bafna Pharmaceuticals Limited has informed the Exchange that Intimation under Regulation 30(5) of SEBI (LODR) Regulations authorization Key managerial personnel for disclosure to the Exchange(s).

Bafna Pharmaceuticals Limited has informed the Exchange regarding the outcome of the Board of Directors of the Company at their meeting held on February 11, 2016: 1. Appointment of Chief Financial Officer.

Bafna Pharmaceuticals Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended December 31, 2015.

Bafna Pharmaceuticals Limited has informed the Exchange that the trading window for dealing in securities of the Company by the Directors and employees will remain closed from January 28, 2016 and shall be opened 48 (Forty Eight) hours after the financials results are approved by the Board of Directors on February 11, 2016.

Bafna Pharmaceuticals Limited has submitted to the Exchange a copy of the Minutes of the Annual General Meeting of the Members of the Company held on September 29, 2015.

Bafna Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 30-Sep-2015.

Bafna Pharmaceuticals Limited has informed the Exchange that the trading window for dealing in securities of the Company by the Directors and employees will remain closed from the date of receipt of this communication till 48 hours after the announcement of the results made to the public.

Bafna Pharmaceuticals Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Members of the Company held on September 29, 2015.

Bafna Pharmaceuticals Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on the September 29, 2015 along with Report of Scrutinizer pursuant to clause 35A of the Listing Agreement.

Bafna Pharmaceuticals Limited has informed the Exchange that the Company has fixed September 22, 2015, as a cut-off date to record the entitlement of Members to cast their votes electronically for the business to be transacted at the ensuing Annual General Meeting of the Company.

Bafna Pharmaceuticals Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from September 23, 2015 to September 29, 2015 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on September 29, 2015.

Bafna Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 30-Jun-2015.

Bafna Pharmaceuticals Limited has informed the Exchange that the trading window for dealing in securities of the Company by the Directors and employees will remain closed from the date of receipt of this communication till 48 hours after the announcement of the results made to the public.

Bafna Pharmaceuticals Limited has informed the Exchange that, consequent upon the intimation given to on March 02, 2015 about the successful completion of MHRA audit process, the company has got the Renewal certificate from MHRA, London.

Bafna Pharmaceuticals Limited has informed the Exchange regarding outcome of the Board Meeting held on May 29, 2015

Bafna Pharmaceuticals Limited has informed the Exchange regarding "Disclosure under SEBI (Prohibition of Insider Trading) Regulations 2015".

Bafna Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2015.

Bafna Pharmaceuticals Limited has informed the Exchange that the trading window for dealing in securities of the Company by the Directors and employees will remain closed from the May 14, 2015 till 48 hours after the announcement of financial results made to the public.

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on March 27, 2015 has appointed Mrs. K. Sabitha as an Additional Director (Woman Director) of the Company. The appointment of Mrs. K. Sabitha is subject to the approval of the shareholders at the ensuing General Meeting.

Bafna Pharmaceuticals Limited has informed the Exchange that the Company have successfully cleared the renewal of audit process as per the guidelines issued by the Medicine and Healthcare Product Agency (MHRA- UK) for European Union GMP.

Bafna Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 31-Dec-2014.

Bafna Pharmaceuticals Limited has informed the Exchange that the trading window for dealing with securities of the Company will be closed for the employees & Directors w.e.f. February 2, 2015 till the date of Board Meeting (both days inclusive). It will reopen after 24 hours of the publication of the results.

Bafna Pharmaceuticals Limited has informed the Exchange that CRISIL has upgraded the Company's rating as CRISIL BB-/stable (Upgraded from CRISIL D) for Long Term rating & CRISIL A4+ (Upgraded from CRISIL D) for Short term Rating in respect of Total bank facilities.

Bafna Pharmaceuticals Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Bafna Pharmaceuticals Limited has informed the Exchange that the trading window for dealing with securities of the Company will be closed for the employees & Directors w.e.f. October 27, 2014 till the date of Board Meeting (both days inclusive).

Bafna Pharmaceuticals Limited has informed the Exchange that Mr. R. S. Gowdhaman is appointed as the Company Secretary & Compliance Officer with effect from October 15, 2014 in place of Mr. K. Premnath who has resigned from the service of the Company.

Bafna Pharmaceuticals Limited has submitted to the Exchange a copy of voting results of Annual General Meeting held on September 10, 2014 along with Report of Scrutinizer pursuant to clause 35A of the Listing Agreement.